Trendlines Portfolio Company Vensica Medical Receives US$2 Million Investment from Cogentix Medical
Vensica is Developing Innovative Device for Delivery of Drugs to the Bladder

Cogentix Holds Option to Acquire the entire share capital of Vensica if Business and Clinical Milestones Achieved

MISGAV, Israel, 2 October, 2017 – Cogentix Medical, Inc. (NASDAQ: CGNT) ("**Cogentix**"), a global medical device company focused on providing the Urology, Uro/Gyn and Gynecology markets with innovative and proprietary products, recently announced a US$2 million investment ("**Investment**") in Vensica Medical Ltd. ("**Vensica**"), a portfolio company of The Trendlines Group Ltd. ("**The Trendlines Group**"). The Trendlines Group has an effective interest of 33.58%, on a fully diluted basis, in Vensica as of immediately prior to the Investment (following the Investment The Trendlines Group will hold an effective interest of 26.87%, on a fully diluted basis). Vensica is developing Vensicare, an ultrasound based, needle-free drug delivery system. The initial indication pursued for the Vensicare device will be the delivery of botulinum toxin (such as Botox® or Dysport®) to treat overactive bladder (OAB). Vensica also has intellectual property for the delivery of oncology agents to the bladder. Vensica currently anticipates commencing human clinical trials of Vensicare for OAB during the fourth quarter of 2018. Cogentix will receive one seat on the Vensica board of directors and according to an option agreement signed between Cogentix, Vensica and Vensica equity holders ("**Option Agreement**"), options to acquire from the equity holders (i.e. shareholders and option holders) of Vensica, including from The Trendlines Group (collectively, the "**Equity Holders**"), the entire share capital of Vensica for an additional US$8 million, as follows:

- An option to acquire, from the shareholders of Vensica, including from The Trendlines Group, an additional 20% of the outstanding shares of Vensica for US$2 million, payable 50% in cash and 50% in Cogentix common stock. This option may be exercised at Cogentix's discretion at any time and expires, if not previously exercised, 30 days subsequent to when Vensica enters into a development and supply agreement with a Botulinum toxin manufacturer (the "**First Milestone**").
- An option to acquire, from the Equity Holders, the remaining share capital of Vensica for an additional US$6 million, payable 50% in cash and 50% in Cogentix common stock. The option may be exercised at Cogentix's discretion at any time and expires if (a) not previously exercised 30 days subsequent to when Vensica delivers to Cogentix a three-month follow up report on the human clinical data from the Vensica trial (the "**Second Milestone**"), or (b) if the first option to acquire an additional 20% of the outstanding shares of Vensica for US$2 million, described above, has not been exercised.
- In the event the Second Milestone occurs prior to the First Milestone, Cogentix will have an option to acquire, from the Equity Holders, the entire share capital of Vensica for US$8 million, payable 50% in cash and 50% in Cogentix common stock. The option may be exercised at Cogentix's

discretion at any time and expires, if not previously exercised, 30 days subsequent to the occurrence of the Second Milestone.

According to the terms of the Option Agreement, The Trendlines Group as well as the other Equity Holders have irrevocably agreed and are obligated to sell their interests in Vensica to Cogentix when the relevant option(s) detailed above is/are exercised by Cogentix. The aggregate consideration to be received by The Trendlines Group assuming the exercise of the said options in full by Cogentix, is approximately US$2.6 million, of which 50% will be settled in cash and 50% in Cogentix common stock ("**Consideration**"). The Consideration is based on arm's length negotiations after taking into account, *inter alia*, applicable market and commercial prospects of Vensica.

The fair value of The Trendlines Group's holdings in Vensica was approximately US$860,000 as at 30 June 2017. Should the options be exercised in full by Cogentix, The Trendlines Group is expected to receive net proceeds of approximately US$2.6 million and a net gain after tax of approximately US$1.3 million.

"We are very excited about the potential the Vensicare product may provide for patients in the US suffering from overactive bladder and its symptoms. The ability to offer another minimally invasive treatment option and significantly increase the number of patients who receive a 3rd line therapy for OAB is truly an exciting opportunity to leverage our strong urology market presence. Our physician customers often use Botox for the treatment of overactive bladder, and we believe Vensica's approach and product pathway currently show promise for revolutionizing the manner in which Botox is administered for OAB," said Darin Hammers, Cogentix President and CEO.

"We are thrilled to partner with Cogentix as we continue the development of Vensicare," said Avner Geva, CEO of Vensica. "We believe that Cogentix is the most attractive partner for Vensica given their knowledge of the OAB market and their successful track record with Urgent PC.[1] We are confident this partnership will result in maximizing the potential of Vensicare."

"Todd Dollinger, Chairman and CEO of The Trendlines Group, congratulated Mr. Geva on Vensica's great achievement and noted that "this collaboration represents an important step in bringing this much-needed product to market."

Financial Effects

The financial effects in the event the options detailed above are exercised by Cogentix in full on The Trendlines Group as set out below are for illustrative purposes only and do not reflect the actual financial performance or position of The Trendlines Group after the exercise of the options in full by Cogentix, and are based on the assumption of receipt of the entire Consideration by the Trendlines Group in the event of such exercise of the options in full.

The effect on the earnings per share as set out below have been prepared based on the latest audited consolidated financial statements of The Trendlines Group for the financial year ended 31 December 2016 ("**FY2016**") and on the assumption that the options detailed above are exercised in full by Cogentix on 1 January 2016:

[1] Urgent PC is a non-drug, non-surgical option for overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

	Before the options detailed above are exercised in full by Cogentix	**After the options detailed above are exercised by Cogentix in full (assuming the achievement of the First and Second Milestone)**
Net loss (US$'000)	(6,578)	(5,232)
Number of shares ('000)	508,742	508,742
Loss per share (US$)	(0.0129)	(0.0103)

Based on the latest audited consolidated financial statements of the Group for FY2016 and on the assumption that the options detailed above are exercised in full by Cogentix on 31 December 2016, the effect of the options detailed above if they are exercised in full on The Trendlines Group's net tangible assets per share as at 31 December 2016 is not material.

None of The Trendlines Group's Directors, substantial shareholders and/or any of their respective associates has any interest, direct or indirect (other than through their shareholdings in The Trendlines Group), in the aforementioned.

The Trendlines Group will provide further updates via SGXNET, if and when there are any material developments to the Trendlines Group in relation to the aforementioned.

About The Trendlines Group

The Trendlines Group is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. As intensely hands-on investors, The Trendlines Group is involved in all aspects of its portfolio companies from technology development to business building. The Trendlines Group's shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

About Cogentix Medical

Cogentix Medical, Inc., headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company. Cogentix design, develop, manufacture and market products for flexible endoscopy with its unique PrimeSight™ product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier providing users with efficient and cost effective endoscope turnover while enhancing patient safety. Cogentix also commercialize the Urgent® PC Neuromodulation System, an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects adults. Cogentix also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Cogentix Medical and its products, please visit it at www.cogentixmedical.com.

Investor Contact Information

Israel:
Judith Kleinman, Director, Investor Relations & Corporate Communications
The Trendlines Group
judith@trendlines.com
Tel: +972.72.260.7000

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST.

The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).